Gene therapy for wet age-related macular degeneration
Treatments studied
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 85 years old
- You have been diagnosed with wet AMD in at least one eye
- You have had a cataract surgery (your eye lens is artificial, called pseudophakia)
- You have had good response to previous eye injections of aflibercept (Eylea)
- Your vision in the study eye is between 20/200 and 20/20 on an eye chart
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
This trial tests an investigational eye injection called AL-001 for people with wet age-related macular degeneration (AMD) that has responded to previous anti-VEGF treatment. The goal is to see if it improves vision and is safe.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.